STOCK TITAN
  1. Home
  2. News
  3. TELO

Telomir Pharmaceuticals, Inc. - $TELO STOCK NEWS

Welcome to our dedicated page for Telomir Pharmaceuticals news (Ticker: $TELO), a resource for investors and traders seeking the latest updates and insights on Telomir Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Telomir Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Telomir Pharmaceuticals's position in the market.

News
Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.
Rhea-AI Summary
Telomir Pharmaceuticals presents promising pre-clinical data on Telomir-1 at a National Press Club event, showcasing a 40% increase in telomerase activity and lengthening of telomeres in human cells. The company plans to initiate human clinical trials for osteoarthritis and veterinary trials in 2025 after pre-clinical studies in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.32%
Tags
clinical trial
-
News
Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024
Rhea-AI Summary
Telomir Pharmaceuticals, Inc. announces promising pre-clinical research on Telomir-1, a novel small molecule that elongates telomere caps to potentially address age-related conditions. The company will present research findings at the National Press Club in Washington, DC. Telomir-1 aims to stimulate stem cell renewal and treat age-related conditions like osteoarthritis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
conferences clinical trial
-
News
UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
Rhea-AI Summary
Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) and Argenta to conduct a study on the efficacy of Telomir-1 in treating osteoarthritis in canines. The study aims to evaluate the potential of Telomir-1 to mitigate the clinical signs of osteoarthritis and other age-related diseases, with the possibility of extending its use to humans. Telomir-1 could offer a disease-modifying therapy for canines, enhancing their quality of life and mobility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.02%
Tags
none
News
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
Rhea-AI Summary
Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) initiates a study with Argenta to evaluate Telomir-1 for treating osteoarthritis in canines, potentially paving the way for human trials. The study aims to assess Telomir-1's efficacy in mitigating osteoarthritis symptoms and other age-related diseases, with a focus on telomere regeneration. Telomir-1 could offer a disease-modifying therapy for canines, addressing a significant unmet medical need in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
none
-
News
Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th
Rhea-AI Summary
Telomir Pharmaceuticals presents pre-clinical results demonstrating Telomir-1's potential to elongate telomeres, addressing age-related conditions. The company aims to showcase its research at the Global Longevity Federation Conference, highlighting positive data on telomere extensions in human cell lines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.42%
Tags
clinical trial
-
News
Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate’s Potential in DNA Age Reversal Science
Rhea-AI Summary
Telomir Pharmaceuticals highlights the potential of Telomir-1 to reverse age-related conditions through computer-aided pre-clinical testing. The company's use of AI-driven in silico modeling supports the therapeutic potential of Telomir-1 in combating age-related diseases. Telomir's upcoming presentations at scientific conferences demonstrate its commitment to advancing anti-aging science.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.83%
Tags
AI
News
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference
Rhea-AI Summary
Telomir Pharmaceuticals, Inc. (TELO) and Frontage Laboratories presented pre-clinical data at the NUHS Conference 2024, showcasing Telomir-1's ability to lengthen telomeres on human stem cells. The data suggests potential for reversing age-related conditions, with promising results that could revolutionize aging processes and extend human life.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
clinical trial
-
News
Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal
Rhea-AI Summary
Telomir Pharmaceuticals, Inc. announces Dr. Roizen as Special Advisor on Age Reversal, leveraging his expertise in age-related medicine to guide the development of Telomir-1, a potential treatment to extend human life by reversing age-related decline. Dr. Roizen's extensive background in wellness and longevity, along with his successful ventures and scientific contributions, align with Telomir's commitment to innovation in the pharmaceutical industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
-
News
Telomir Pharmaceuticals Announces Closing of Initial Public Offering
Rhea-AI Summary
Telomir Pharmaceuticals, Inc. (TELO) successfully completed its initial public offering of 1,000,000 shares at $7.00 per share, raising $7 million. The company focuses on developing Telomir-1, a novel small molecule for age reversal by lengthening DNA telomere caps. The shares started trading on Nasdaq under the symbol TELO, with Kingswood Investments as the book-running manager.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
69.76%
Tags
IPO offering
Stock TELO logo
Telomir Pharmaceuticals, Inc.

Nasdaq:TELO

TELO Rankings

#3859 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

TELO Stock Data

185.95M
29.61M
Pharmaceutical Preparations
United States of America
TAMPA